Science ❯ Biotechnology ❯ Drug Development

Clinical Trials

GLP-1 Receptor Agonists Therapeutic Innovations Weight Loss Mechanisms Phase 3 Trials FDA Approvals Peptide Research Psychedelic Research FGF21 Analog Phase 3 Studies siRNA Therapeutics T-cell Engager Therapies Animal Health Immunology Drugs Phase I Trials Mast Cell Biology Long-Acting Injectables Biosimilar Products Cancer Research Safety Regulations ADC Technology Regulatory Approval Cancer Drugs Liver Treatments Antisense Oligonucleotide Conjugates Psychedelic Substances Phase III Trials Regulatory Approvals Orexin Receptor Agonists Lung Cancer BNT327 Weight Loss Therapies Anktiva Immuno-Oncology Oncology Cell Therapy Biosimilar Medicines VG-3927 RSV and Cancer Vaccines

UCB to Buy Candid Therapeutics for Up to $2.2 Billion

The buyout expands UCB's push into T‑cell engager drugs for autoimmune diseases.

Trump Order to Speed Psychedelic Therapies Sends Compass Pathways to 52-Week High

Kailera Leaps 62% in Nasdaq Debut After $625 Million IPO

Viking Therapeutics Pushes VK2735 Through Pivotal Trials as Next Enrollment Milestone Nears

EU Grants Conditional Approval for ImmunityBio’s Anktiva in BCG‑Unresponsive Bladder Cancer

ImmunityBio Extends Rally to 52-Week High on Anktiva Sales, Saudi Approval and Trial Progress

Zydus to Commercialize FDA-Approved Interchangeable Lucentis Biosimilar NUFYMCO in U.S. Under Bioeq Deal

Tubulis Raises €308 Million Series C to Accelerate Lead Cancer ADC

Novo Nordisk to Acquire Akero for Up to $5.2 Billion to Expand in MASH

Weekly Parkinson’s Injection Secures Patent After Successful Lab Trials

Merck to Acquire Verona Pharma in $10 Billion Deal for Ohtuvayre COPD Therapy

Sanofi to Acquire Blueprint Medicines for $9.1 Billion, Boosting Its Rare Immunology Pipeline

Sanofi to Acquire Vigil Neuroscience in $600M Deal to Advance Alzheimer’s Research